UCB
UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis
May 29, 2018Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis
The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …
FDA refuses approval of Amgen osteoporosis drug
July 17, 2017Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical
Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …
US court rules in favour of UCB in patent dispute, shares jump
August 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat
UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …
Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis
July 13, 2016Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis
The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …
UCB scores Japanese approval for seizure therapy, Vimpat
July 5, 2016Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
Further positive trial results boost Amgen and UCB’s romosozumab
March 21, 2016Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval
Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
Amgen and UCB announce positive romosozumab results
February 22, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis
Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
AbbVie VP joins UCB Pharma
January 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma
Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …
UCB appoints Steve Turley as MD for Britain and Ireland
November 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB
Steve Turley has joined UCB as the company’s managing director for the British and Irish isles, moving from Lundbeck. He …
UCB plots new Vimpat submissions after positive monotherapy results
October 8, 2015Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat
A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Funding boost for UK drugs manufacturing
March 30, 2015Manufacturing and Production, Sales and Marketing ABPI, AstraZeneca, BIA, Bristol-Myers Squibb, Britest, Cambridge, Cambridge Crystallographic Data Centre, GlaxoSmithKline, Perceptive Engineering, Pfizer, Process Systems Enterprise, UCB, University of Leeds, amsci, mmip, stfc
The UK government is funding new manufacturing partnerships that will improve design processes and supply chain initiatives to lift the …
Big pharma teams with government on genomic research
March 27, 2015Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes
Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …
UCB sponsors ‘Hack Epilepsy’ digital event
March 12, 2015Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat
Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …
UCB’s new chief executive picked as EU rep for MISG
February 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jean-Christophe Tellier, MISG, UCB
UCB’s newly-appointed chief executive Jean-Christophe Tellier has been selected to join the Ministerial Industry Strategy Group (MISG). Elected to the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
